Fabhalta 200 mg
As listed in the register: Fabhalta 200 mg, Hartkapseln
200 mg ·
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Iptacopanum
- Made by
- Novartis Pharma Schweiz AG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Als Monotherapie für die Behandlung erwachsener Patienten mit paroxysmaler nächtlicher Hämoglobinurie (PNH), die trotz einer mindestens 6-monatigen Behandlung mit einem C5-Inhibitor unzureichend angesprochen hatten. Zur Behandlung erwachsener Patienten mit Komplement-3-Glomerulopathie (C3G) in Kombination mit einem Renin-Angiotensin-System (RAS)-Inhibitor oder bei Patienten, die intolerant gegen RAS-Inhibitoren sind oder bei denen ein RAS-Inhibitor kontraindiziert ist.
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Novartis Pharma Schweiz AG |
|---|---|
| Active substance | Iptacopanum |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 200 mg |
| Classification | L04AJ08 · Cancer treatments and immune-system medicines |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Name in the register | Fabhalta 200 mg, Hartkapseln |
| Packs | 56 Kapsel(n) |
| Zulassungsnummer | 68603 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.